Basel-based Atlas Bio has raised $12.5M led by Creandum to use AI to simulate Phase II drug trials. First trial results are expected in about six weeks ...

Swiss startup Atlas Bio raises $12.5M to build in silico clinical trials and tackle the 70% Phase II failure rate. What is ...

The Swiss startup is developing an AI foundation model that predicts drug efficacy and safety in virtual patients, ...

Climb Bio, Inc. announced initial PrisMN Phase 2 data for budoprutug, its anti-CD19 monoclonal antibody, in primary membranous nephropathy (“pMN”). PrisMN is an ongoing Phase 2 dose-escalation trial ...

Boost ROI with AI-enabled automation, advanced assays, integrated data systems and global partnerships that accelerate compliant drug development.Dublin, Oct. (GLOBE NEWSWIRE) -- "Bioanalytical ...

A novel lytic phage isolated from hospital sewage reduced viable drug-resistant Klebsiella pneumoniae in catheter biofilms by ...

Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, ...

Bio-Techne's shares have gained 10.1% over the past year, underperforming the broader S&P 500 Index ($SPX), which advanced 13.4% over the same period. In fact, the stock has also underperformed its ...

Climb Bio, Inc. (Nasdaq: CLYM, “Climb Bio”) and Beijing Mabworks Biotech Co., Ltd. (“Mabworks”), today announced additional ...

ZURICH, Oct 27 (Reuters) - Swiss AI start-up Atlast Bio, which runs drug trials on virtual patients, has received $12.5 million in funding led by Swedish venture capital firm Creandum, an early backer ...